Houston-based Proxima Clinical Research has expanded its footprint thanks to a recent partnership. Image via proximacro.com

Houston-based Proxima Clinical Research announced this month that it will expand its clinical trial offerings by adding NEXT Oncology to its Early Phase Oncology Network, or EPON.

NEXT Oncology is a Phase I clinical trial treatment center with locations in Austin, Dallas, San Antonio, and Virginia, as well as international locations in Barcelona and Madrid. These centers provide innovative and investigational treatments and therapies to patients with advanced forms of cancers.

The addition of NEXT Oncology's clinics brings Proxima's oncology network up to 14 physical locations and eight clinical practices, Robbin Frnka, executive director of clinical development and strategy at Proxima CRO tells InnovationMap.

“Early phase oncology trials are some of the most delicate and important trials to conduct, both from a science perspective and in offering hope for late-stage patients,” Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, says in a statement. “We proudly designed NEXT Oncology specifically to bring the best new agents to patients through our specially designed centers located around the world. This new relationship with Proxima CRO’s EPON will help us further enhance our mission and contribute to our life’s work of advancing cancer treatments to save more lives from cancer around the world.”

Proxima is a Houston-based contract research organization focused on supporting life science startups as they grow and scale. It was recently named to the the Inc. 5000 regional rankings for the Southwest for its fast-growing revenue.

The company launched its EPON in March to support Phase I and Phase II clinical oncology trials and a group of oncology-specific scientific experts. The Mary Crowley Cancer Research, a specialized clinical research center in Dallas, was one of the first to join the network.

"Finding the right clinical sites and investigators with the right patients is one of the biggest struggles of early phase clinical trials," Frnka says in a March statement. "Our Early Phase Oncology Network, which we're calling EPON, includes some of the most prominent investigators in early phase trials. Receiving expert feedback, insight, and guidance from this skilled scientific panel is critical to the success of these earliest phase trials."

In addition to work in the cancer field, Proxima also launched its M1 MedTech accelerator last year aimed at helping startups quickly grow their health tech businesses. Its inaugural cohort included startups with new tech and treatments for heart arrhythmias, ultrasounds, bioelectric implants in the body and more.

The company also recently expanded its footprint within the Texas Medical Center Innovation Factory.

InnovationMap spoke with Proxima CEO and Co-founder Kevin Coker on the Houston Innovators Podcast.

This week's roundup of Houston innovators includes Kevin Coker of Proxima CRO, Gaurab Chakrabarti of Solugen, and Phil Sitter and Chris Chomenko of RepeatMD. Courtesy photos

4 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to four local innovators across industries — from marketing tech to synthetic biology — recently making headlines in Houston innovation.

Kevin Coker, CEO and co-founder of Proxima CRO, and Gaurab Chakrabarti, CEO and co-founder of Solugen

First Bight VC named two Houstonians to its board. Photos courtesy

First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups founded by Veronica Wu in January, has named two new board members: Gaurab Chakrabarti, co-founder and CEO of Solugen, and Kevin Cocker, co-founder and CEO of Proxima CRO.

"We are excited to announce the addition of Dr. Gaurab Chakrabarti and Kevin Cocker," Wu says in a press release. "These two advisors are experts in their respective fields of medicine and biotechnology. They are proven leaders of Houston-based companies, which is key to our overall growth strategy, as we seek to establish Houston as a geographic center for innovation in Synthetic Biology." Click here to read more.

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko join the Houston Innovators Podcast to explain how they are revolutionizing the aesthetics industry. Photos courtesy

Houston restaurateur pivoted his restaurant marketing business amid the pandemic — to a growing industry: aesthetics. Phil Sitter took the idea and tech he created with VIPInsiders to launch RepeatMD, a customizable marketing and fintech platform focused on the aesthetics industry, which includes plastic surgeons, dermatologists, etc.

Sitter, who serves as the company's CEO, says once he dived into learning about the industry, he found out these types of business are seeing incredible growth following the pandemic.

"They call it the 'Zoom boom' — everyone saw themselves on Zoom daily and decided to invest in themselves and their facial treatments." says Chris Chomenko, vice president of sales for the company, on the Houston Innovators Podcast.

"And they had the time," Sitter adds. "When you think about aesthetic procedures — whether its invasive or non-invasive, it takes time for recovery." Click here to read more.

First Bight Ventures has added two Houstonians to its advisory board. Image via Getty Images

Houston-based synthetic biology investment fund taps 2 prominent advisers for board

on boarding

Earlier this year, a new synthetic biology-focused venture capital fund launched in Houston, and now its added to its esteemed set of advisers.

Veronica Wu, former Apple and Tesla exec, founded First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups, in January and named her initial board members. This month, she's added to those ranks with two Houstonians joining the advisory board — Gaurab Chakrabarti, co-founder and CEO of Solugen, and Kevin Coker, co-founder and CEO of Proxima CRO.

"We are excited to announce the addition of Dr. Gaurab Chakrabarti and Kevin Coker," Wu says in a press release. "These two advisors are experts in their respective fields of medicine and biotechnology. They are proven leaders of Houston-based companies, which is key to our overall growth strategy, as we seek to establish Houston as a geographic center for innovation in Synthetic Biology."

Gaurab co-founded Solugen, a Houston unicorn that creates enzymes that can turn sugar into chemicals, in 2016. He studied computational neuroscience at Brown University and received his master's and PhD in cancer biology and enzymology at the University of Texas.

Representing the health care side of synthetic biology, Kevin Coker runs Houston-based Proxima CRO, a regulatory and clinical partner for the emerging biotech and medical device industry. He is also the founder and partner of the M1 MedTech accelerator and the Host of the Inventing Tomorrow podcast.

"I couldn't be more excited to work with Veronica and First Bight Ventures," Coker says in the release. "The time is now for companies developing Synthetic Biology products and platforms. Much of this technology has reached commercial level maturity and we are beginning to see exciting things happen, particularly in Houston."

The two join six other advisers on the board:

  • Dr. Ethel Rubin, an experienced life sciences executive with commercialization and investment experience across multiple therapeutic areas and modalities.
  • Lekan Akinyanmi, founder and CEO of Cambridge Growth Partners, a holding company with interests in mining, finance, oil/gas, and renewable energy.
  • Dr. Guochun Liao, founder of IDbyDNA, which focuses on utilizing next-generation sequencing and AI/ML for infectious disease management.
  • Mario Maia, leader of the corporate investment arm of Novozymes.
  • Peter Oleksiak, former CFO senior vice president for DTE Energy Co., a Fortune 500 diversified energy compan.
  • Davy Wang, senior director at Oracle Cloud.
Here's what you missed at Houston House at SXSW. Photos courtesy

Podcast: Houston innovators discuss energy transition, diversity, and health tech at SXSW

Houston innovators podcast episode 125

SXSW has descended on Austin, and while the two-week conference and festival is still going strong, the Greater Houston Partnership's Houston-focused activation has wrapped for 2022.

Houston House, which first originated last year in digital form in 2021, took place Sunday, March 13, and Monday, March 14. The nine panels and two nights of networking covered topics from energy transition and med tech to diversity in venture capital and innovation in aerospace.

For SXSW badge holders, some of the Houston House discussions are available online. However if you’re not out and about at SX and you missed these incredible panels, I spoke to four Houstonians after their discussions to dig a little deeper into some key points from the panels.

Here are the Houston Innovators I spoke with at SXSW:

  • Denise Hamilton, CEO of WatchHerWork
  • Kevin Coker, president and CEO, Proxima
  • Grace Chan, investment associate at bp Ventures
  • Dale Winger, managing director of Halliburton Labs

Listen to these conversations below — or wherever you stream your podcasts — and subscribe for weekly episodes, which will return to interview-style conversations featuring Houston guests next Wednesday.

Proxima Clinical Research has its New Year's resolution and is ready to start working hands on with health tech startups. Graphic via proximacro.com

Houston organization plans to launch health tech accelerator in 2022

ready to grow

A contract research organization based in Houston has announced its new accelerator program aimed at helping startups quickly grow their health tech businesses.

Proxima Clinical Research released details of M1 MedTech, which expects to launch early next year. The CRO has raised funds to launch and invest in members of the inaugural cohort.

“Our goal is to move these companies substantially forward in a short amount of time,” says Kevin Coker, CEO of Proxima, in a news release. “Proxima is in a unique position to leverage our experienced team of regulatory, quality, and clinical experts. We won’t be working at arm’s length from these companies. We will be a big part of what they do every day.”

The program will focus on a small group of companies and the Proxima team will provide hands-on support, including instruction, workshops, and one-on-one mentoring.

“This will be a unique experience for all parties involved, as Proxima is also a young, yet established, company that is now creating a program to assist companies at an earlier stage,” says Larry Lawson, co-founder of Proxima, in the release. “Our experience in the CRO realm and ability to provide coaching in clinical, regulatory, quality, and go-to-market strategies will only strengthen M1 MedTech’s ability to support the success of emerging companies and provide more life-saving technology to the public.”

Kevin Coker and Larry Lawson co-founded Proxima in 2017. Photos courtesy

The accelerator will target Class II and III medical devices for its initial cohort. In the future, Proxima plans to expand to include an even more extensive incubator focused solely on Class III devices, according to the release.

“M1 will be a place where startups can go to receive concrete resources to further their development. The participant success is our sole focus, and the ultimate goal is to have a substantial impact on the ideation-to-market process for Class II and Class III medical devices,” says Isabella Schmitt, director of regulatory affairs at Proxima and a principal at M1, in the release. “Proxima’s specific expertise alongside our M1 partners will provide resources for all key areas of a medical device entrepreneur’s journey to market and beyond.”

The M1 MedTech applications will open online in the spring.

“We don’t view M1 as competitive to other accelerators, rather we believe it will offer a different experience. Our team will strive to create a personalized program where companies have a dedicated touch point throughout the process,” says Sean Bittner, director of programs at M1 MedTech, in the release. “We will also provide specific, tailored connections and resources vetted by our team through professional partnerships, not just a general list of industry contacts.”

This week's roundup of Houston innovators includes Emily Cisek of The Postage, Kevin Coker of Proxima Clinical Research, and Sylvia Kampshoff of Kanthaka. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — tech, health care, and more — recently making headlines in Houston innovation.


Emily Cisek, founder of The Postage

The Postage — a Houston-based company that's streamlining afterlife planning — has rolled out a new app. Photo courtesy of The Postage

Emily Cisek had a mission when she founded The Postage. She wanted to make afterlife planning simpler — and she's taken one giant step toward that goal with the company's new app.

"What we wanted to do [with the app] is make it so easy to plan your life and the end of your life using one click — as easy as it was for posting and commenting on social media," explains Cisek. "People are so used to reflecting on those behaviors and clicking one button to add a picture ... we wanted to make it that simple."

Though The Postage's website had mobile functionality, the app includes the ability to record and upload content. Whether snapping a picture of their insurance policy or recording a video to share with loved ones, The Postage app allows users to capture photos and videos directly within the app. Click here to read more.

Kevin Coker, CEO of Proxima Clinical Research

Kevin Coker, CEO of Proxima Clinical Research, say his company transform from uncertainty to almost uncontrollable growth in just 12 months. He shares what happened on this week's episode of the Houston Innovators Podcast. Photo courtesy of Proxima

After a huge dip in business due to the pandemic, a Houston company focused on supporting innovative life science companies saw 12 months of unprecedented growth. Kevin Coker, CEO of Proxima Clinical Research, says that's not only a good sign for the future of his business — but also of the future of Houston's life science sector.

"We're a good barometer for what's happening not only locally but across the country," Coker says. "As Proxima has grown, it's really show how the Houston life science market is growing."

Coker shares more about Proxima's growth and Houston's potential of being a major life science hub on the episode. Click here to read more and stream the episode.

Sylvia Kampshoff, founder of Kanthaka

Sylvia Kampshoff has launched Kanthaka's first crowdfunding campaign. Photo courtesy of Kanthaka

Sylvia Kampshoff has lofty goals for her company Kanthaka, a platform for connecting users to personal trainers across over a dozen cities. With the launch of a new $1 million crowdfunding raise, Kampshoff is one step closer to growing her business according to these goals.

"Our vision is to become Amazon for health & fitness and the go-to provider to live a longer, happier and healthier life," Kampshoff says. "We couldn't be more excited about this journey." Click here to read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston universities climb the ranks on annual list of most patents issued

top 100

The University of Houston and Rice University have claimed spots on the National Academy of Inventor's Top 100 U.S. Universities Granted Utility Patents.

The list is based on data obtained from the U.S. Patent and Trademark Office and ranks U.S. academic institutions that are advancing innovation by the number of utility patents issued in the prior year.

Utility patents are among the world’s most valuable assets because they give inventors exclusive commercial rights to produce and use their technology. The universities ranked on the list collectively hold nearly 6,500 patents.

“In the ever-evolving innovation landscape, it is imperative that the U.S. is remaining competitive and at the forefront of today’s emerging research and technologies,” Paul R. Sanberg, president of the NAI, said in a news release. “Ensuring the security of intellectual property through patenting is a crucial component to this and allows those innovations to be effectively moved to market, where they can create valuable societal and economic impact. The Top 100 U.S. list celebrates U.S. universities and their inventive staff and faculty for their dedication in ensuring their innovations and IP are protected.”

The University of Houston System came in at No. 62 with 34 patents, and Rice University claimed the No. 68 spot with 30 patents.

Both universities climbed up the rankings this year. Last year, UH was ranked No. 63 with 27 patents. Rice climbed an impressive 26 spots this year, after ranking No. 94 with 14 patents issued in 2023.

“Granted U.S. utility patents can tremendously help in commercializing the technologies covered by such patents by attracting industry investment and commercial partners on a global level,” Neha Malik, assistant director for intellectual property management in Rice's Office of Technology Transfer, said in a release. “Advancing in this list memorializes Rice’s commitment to support research programs of Rice faculty by generating a path for the university to bring its research to the marketplace.”

Other Texas universities on the list include:

  • No. 3 University of Texas System (234 patents)
  • No. 35 The Texas A&M System (61 patents)
  • No. 73 Texas Tech University System (25 patents)
  • No. 80 Baylor University (20 patents)

The University of California (540 patents) claimed the No. 1 spot again this year, followed by the Massachusetts Institute of Technology (295 patents), which also placed second for 2024.

First large-scale affordable housing project of 3D-printed homes rises in Houston

Building Blocks

What’s being promoted as the world’s first large-scale affordable housing development built using 3D technology is taking shape in Houston.

Houston-based 3D construction company HiveASMBLD has teamed up with Houston-based Cole Klein Builders and the City of Houston on the Zuri Gardens project. Located near Hobby Airport on Martindale Road, the first 3D-printed home at Zuri Gardens is set to be completed in October.

“Zuri Gardens was born from the frustration of watching hardworking families get priced out of safe, resilient housing. We knew there had to be a better way — and with this project, we’re proving that there is,” says Vanessa Cole, co-founder of Cole Klein Builders.

“By combining visionary design, advanced construction technology, and powerful partnerships, we’re building more than just homes — we’re creating a blueprint for the future of equitable homeownership in Houston and beyond.”

The development is being created for households earning up to 120 percent of the median income in the Houston metro area. For a four-member household in the Houston area, the 120 percent limit in 2025 is $121,300, as set by the U.S. Department of Housing and Urban Development (HUD).

The 13-acre Zuri Gardens development will feature 80 energy-efficient homes averaging 1,360 square feet. Prices will be in the mid to high $200s. The homes will qualify for up to $125,000 in down payment assistance from the City of Houston.

HiveASMBLD will print two different home designs, each with two-bedroom and two-and-a-half bathroom configurations, along with an office/flex space and a covered patio.

Zuri Gardens home model Houston Courtesy rendering

“The community we envision for Zuri Gardens is modern, safe, and one that residents will be proud to call home. When completed using HiveASMBLD’s innovative technology, this 3D-printed multifamily community will exemplify the future of residential affordable living,” says Timothy Lankau, founder and co-CEO of HiveASMBLD.

Developments like Zuri Gardens are popping up around the country.

“3D-printed homes are revolutionizing the construction industry by making home builds faster, cheaper, and more sustainable,” according to The Zebra, an Austin-based insurance marketplace. “In less than 24 hours, 3D printers can print the foundation and walls for a small home at a fraction of the cost of typical construction.”

U.S. News & World Report explains that unlike a traditional home, a 3D-printed home is printed in place, “just like you’d print a knickknack on your home 3D printer. Layer by layer, proprietary concrete blends are used to build the wall systems of the home in any type of design that a builder can imagine.”

Texas is home to several trailblazing 3D-printed projects.

In the U.S., the first 3D-printed home was built in 2018 in Austin, and the first 3D-printed multistory home was completed in 2023 in Harris County’s Spring Branch neighborhood. Meanwhile, the world’s largest neighborhood of 3D-printed homes is located in the Austin suburb of Georgetown.

Grand View Research predicts the global market for 3D-printed construction will approach $4.2 billion by 2030.

---

This article originally appeared on CultureMap.com.

Houston tech company secures $450M NASA contract

space deal

NASA’s Johnson Space Center awarded Houston-based aerospace technology and engineering services company Barrios Technology the Mission Technical Integration Contract (MTIC).

The two-year contract is worth $450 million and will begin Oct. 1, 2025.

Barrios will provide technical and management support to some of NASA’s human spaceflight programs, which include the Orion and Gateway programs, the International Space Station (ISS) and possibly more human spaceflight initiatives.

The contract represents a continuation of Barrios’ Human Space Flight Technical Integration Contract (HSFTIC), which has been in effect since 2020.

“We are incredibly proud to have been selected by NASA to continue working side by side with them in shaping the future of human space exploration,” Kelly Page, president of Barrios Technology, said in a news release.

The contract also includes support for program, business, configuration and data management, information technology, systems engineering and integration, mission integration, safety and mission assurance, and operations according to Barrios.

Barrios will be supported by subcontractors ARES Technical Services Corp., Booz Allen Hamilton, Intuitive Machines, Summit Technologies & Solutions, and TechTrans International (TTI).

“This award is a testament to the passion, hard work, and extraordinary value that our Barrios family brings every single day,” Page added in the release. “This is not just another contract award—it is the continuation of a generational commitment to our NASA customers and their critical missions.”